Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-03-10
2011-10-04
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000
Reexamination Certificate
active
08030275
ABSTRACT:
The present invention provides methods for reducing body weight in a mammal using Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 4970154 (1990-11-01), Chang
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5106627 (1992-04-01), Aebischer et al.
patent: 5217889 (1993-06-01), Roninson et al.
patent: 5234784 (1993-08-01), Aslam et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5272071 (1993-12-01), Chappel
patent: 5364791 (1994-11-01), Vegeto et al.
patent: 5489743 (1996-02-01), Robinson et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5557032 (1996-09-01), Mak
patent: 5585089 (1996-12-01), Queen et al.
patent: 5589362 (1996-12-01), Bujard et al.
patent: 5593875 (1997-01-01), Wurm et al.
patent: 5635399 (1997-06-01), Kriegler et al.
patent: 5650298 (1997-07-01), Bujard et al.
patent: 5654168 (1997-08-01), Bujard et al.
patent: 5672510 (1997-09-01), Eglitis et al.
patent: 5676954 (1997-10-01), Brigham
patent: 5679559 (1997-10-01), Kim et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5811234 (1998-09-01), Roninson et al.
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 6150098 (2000-11-01), Zhang
patent: 6639063 (2003-10-01), Edwards
patent: 6716626 (2004-04-01), Itoh
patent: 7259248 (2007-08-01), Itoh
patent: 7408047 (2008-08-01), Thomason
patent: 7491697 (2009-02-01), Beals
patent: 2001/0012628 (2001-08-01), Agarwal
patent: 2002/0081663 (2002-06-01), Conklin
patent: 2002/0164713 (2002-11-01), Itoh
patent: 2003/0220246 (2003-11-01), Conklin
patent: 2004/0018499 (2004-01-01), Lal
patent: 2004/0185494 (2004-09-01), Itoh
patent: 2004/0259780 (2004-12-01), Glasebrook
patent: 2005/0037457 (2005-02-01), Itoh
patent: 2005/0176631 (2005-08-01), Heuer
patent: 2007/0036806 (2007-02-01), Glaesner
patent: 2007/0128619 (2007-06-01), Itoh
patent: 2007/0142278 (2007-06-01), Beals
patent: 2007/0237768 (2007-10-01), Glaesner
patent: 2007/0238657 (2007-10-01), Itoh
patent: 2007/0265200 (2007-11-01), Glaesner
patent: 2007/0293430 (2007-12-01), Frye
patent: 2007/0299007 (2007-12-01), Frye
patent: 2008/0071065 (2008-03-01), Thomason
patent: 2008/0071066 (2008-03-01), Thomason
patent: 2008/0103096 (2008-05-01), Frye
patent: 2008/0255045 (2008-10-01), Cujec
patent: 2008/0261236 (2008-10-01), Kuro-o
patent: 2008/0261875 (2008-10-01), Etgen
patent: 2009/0074776 (2009-03-01), Itoh
patent: 0036676 (1981-09-01), None
patent: 0058481 (1982-08-01), None
patent: 0088046 (1983-09-01), None
patent: 0133988 (1985-03-01), None
patent: 0143949 (1985-06-01), None
patent: 0154316 (1985-09-01), None
patent: 0401384 (1990-12-01), None
patent: 0505500 (1992-09-01), None
patent: 0315456 (1994-06-01), None
patent: 0546073 (1997-09-01), None
patent: 90/04036 (1990-04-01), None
patent: 91/09955 (1991-07-01), None
patent: 91/10425 (1991-07-01), None
patent: 91/10470 (1991-07-01), None
patent: 91/10741 (1991-07-01), None
patent: 93/15722 (1993-08-01), None
patent: 94/02602 (1994-02-01), None
patent: 94/20069 (1994-09-01), None
patent: 94/28122 (1994-12-01), None
patent: 95/05452 (1995-02-01), None
patent: 95/34670 (1995-12-01), None
patent: 96/11953 (1996-04-01), None
patent: 96/32478 (1996-10-01), None
patent: 96/33735 (1996-10-01), None
patent: 96/37609 (1996-11-01), None
patent: 96/40958 (1996-12-01), None
patent: 96/41865 (1996-12-01), None
patent: 97/31899 (1997-09-01), None
patent: 97/34631 (1997-09-01), None
patent: 99/10494 (1999-03-01), None
patent: 00/24782 (2000-05-01), None
patent: 00/54813 (2000-09-01), None
patent: 01/18172 (2001-03-01), None
patent: 01/18209 (2001-03-01), None
patent: 01/32678 (2001-05-01), None
patent: 01/36640 (2001-05-01), None
patent: 01/38357 (2001-05-01), None
patent: 01/49849 (2001-07-01), None
patent: 01/72957 (2001-10-01), None
patent: 03/011213 (2003-02-01), None
patent: 03/059270 (2003-07-01), None
patent: 04110472 (2004-12-01), None
patent: 05061712 (2005-07-01), None
patent: 05072769 (2005-08-01), None
patent: 05/091944 (2005-10-01), None
patent: 05/113606 (2005-12-01), None
patent: 06/028595 (2006-03-01), None
patent: 06/028714 (2006-03-01), None
patent: 06/050247 (2006-05-01), None
patent: 06/065582 (2006-06-01), None
patent: 06/078463 (2006-07-01), None
patent: 07/055789 (2007-05-01), None
patent: 07/100695 (2007-09-01), None
patent: 08/011633 (2008-01-01), None
patent: 08/121563 (2008-10-01), None
patent: 08/151258 (2008-12-01), None
patent: 08/153705 (2008-12-01), None
patent: 09/020802 (2009-02-01), None
The ADHR consortium (2000), “Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.” Nature Genetics 26: 345-348.
Arner et al. (2008) “FGF21 attenuates lipolysis in human adipocytes—A possible link to improved insulin sensitivity” FEBS Letters 582: 1725-1730.
Artuc et al. (1999), “Mast cells and their mediators in cutaneous wound healing—active participants or innocent bystanders?” Exp. Dermatol. 8: 1-16.
Bayer et al., 1990, “Protein biotinylation” Meth. Enz. 184: 138-63.
Beck and Podolsky (1999), “Growth factors in inflammatory bowel disease.” Inflamm. Bowel Dis. 5: 44-60.
Bishop (1996), “Chromosomal insertion of foreign DNA,” Reprod. Nutr. Dev. 36(6): 607-18.
Bork et al. (1996), “Go hunting in sequence databases but watch out for the traps,” Trends Genet. 12(10): 425-27.
Bork et al. (1998), “Predicting functions from protein sequences—where are the bottlenecks?” Nature Genetics 18(4): 313-18.
Bork (2000), “Powers and pitfalls in sequence analysis: the 70% hurdle,” Genome Res. 10(4): 398-400.
Branch (1998), “A good antisense molecule is hard to find.” Trends Biochem Sci. 23(2): 45-50.
Brenner (1999), “Errors in genome annotation,” Trends Genet. 15(4): 132-33.
Brodeur et al., Monoclonal Antibody Production Techniques and Applications 51-63 (Marcel Dekker, Inc., 1987).
Bruggermann et al., (1993), “Designer mice: the production of human antibody repertoires in transgenic animals” Year in Immuno. 7: 33.
Capon et al., (1989), “Designing CD4 immunoadhesins for AIDS therapy” Nature 337: 525-31.
Debernardez Clark E., (1998), “Refolding of recombinantroteins” Curr. Opin. Biotechnol. 9. 157-63.
Cunha et al. (1996), “Keratinocyte growth factor as mediator of mesenchymal-epithelial interactions in the development of androgen target organs.” Semin Cell Dev Biol 7: 203-210.
Ausubel, et al., Current Protocols in Molecular Biology (Ausubel et al., eds., Green Publishers Inc. and Wiley and Sons 1994).
Dailey, et al. (2005), “Mechanisms underlying differential responses to FGF signaling,” Cytokine & Growth Factor Reviews 16: 233-247.
Doerks et al. (1998), “Protein annotation: detective work for function prediction,” Trends Genet. 14(6): 248-50.
Ebadi et al. (1997), “Neurotrophins and their receptors in nerve injury and repair.” Neurochem. Int. 30: 347-74.
Econs and McEnery (1997) “Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder.” J Clin Endocrinol Metab 82:674-681.
Ellison et al., (1982), “The nucleotide sequence of a human immunoglobulin Cγ1 gene” Nucleic Acids Res. 10: 4071-9).
Eppstein, et al., (1985) “Biological activity of liposome-encapsulated murine interferon y is mediated by a cell membrane receptor” Proc. Natl. Acad. Sci. U.S.A. 82:3688-92.
Freiberg & Zhu, (2004) &
Liu Benxian
Thomason Arlen
Amgen Inc.
McDonnell & Boehnen Hulbert & Berghoff
Saoud Christine J
LandOfFree
Methods for treating obesity using fibroblast growth... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating obesity using fibroblast growth..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating obesity using fibroblast growth... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263327